Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Tumor analysis: freeze-thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells.

Le Gallo M, de la Motte Rouge T, Poissonnier A, Lavoué V, Tas P, Leveque J, Godey F, Legembre P.

BMC Res Notes. 2018 Jun 20;11(1):401. doi: 10.1186/s13104-018-3504-5.

2.

CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases.

Le Gallo M, Poissonnier A, Blanco P, Legembre P.

Front Immunol. 2017 Sep 27;8:1216. doi: 10.3389/fimmu.2017.01216. eCollection 2017. Review.

3.

The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.

Le Gallo M, Rudd ML, Urick ME, Hansen NF; National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program, Merino MJ, Mutch DG, Goodfellow PJ, Mullikin JC, Bell DW.

Cancer. 2018 Jan 1;124(1):65-73. doi: 10.1002/cncr.30971. Epub 2017 Sep 21.

PMID:
28940304
4.

Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.

Le Gallo M, Rudd ML, Urick ME, Hansen NF, Zhang S; NISC Comparative Sequencing Program, Lozy F, Sgroi DC, Vidal Bel A, Matias-Guiu X, Broaddus RR, Lu KH, Levine DA, Mutch DG, Goodfellow PJ, Salvesen HB, Mullikin JC, Bell DW.

Cancer. 2017 Sep 1;123(17):3261-3268. doi: 10.1002/cncr.30745. Epub 2017 May 9.

5.

CD95 Stimulation with CD95L and DISC Analysis.

Le Gallo M, Legembre P.

Methods Mol Biol. 2017;1557:11-18. doi: 10.1007/978-1-4939-6780-3_2.

PMID:
28078578
6.

Next-Generation Sequencing.

Le Gallo M, Lozy F, Bell DW.

Adv Exp Med Biol. 2017;943:119-148. Review.

PMID:
27910067
7.

CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice.

Poissonnier A, Sanséau D, Le Gallo M, Malleter M, Levoin N, Viel R, Morere L, Penna A, Blanco P, Dupuy A, Poizeau F, Fautrel A, Seneschal J, Jouan F, Ritz J, Forcade E, Rioux N, Contin-Bordes C, Ducret T, Vacher AM, Barrow PA, Flynn RJ, Vacher P, Legembre P.

Immunity. 2016 Jul 19;45(1):209-23. doi: 10.1016/j.immuni.2016.06.028.

8.

The mutational landscape of endometrial cancer.

Hong B, Le Gallo M, Bell DW.

Curr Opin Genet Dev. 2015 Feb;30:25-31. doi: 10.1016/j.gde.2014.12.004. Epub 2015 Jan 23. Review.

9.

Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.

Rudd ML, Mohamed H, Price JC, O'Hara AJ, Le Gallo M, Urick ME; NISC Comparative Sequencing Program, Cruz P, Zhang S, Hansen NF, Godwin AK, Sgroi DC, Wolfsberg TG, Mullikin JC, Merino MJ, Bell DW.

BMC Cancer. 2014 Nov 26;14:884. doi: 10.1186/1471-2407-14-884.

10.

The emerging genomic landscape of endometrial cancer.

Le Gallo M, Bell DW.

Clin Chem. 2014 Jan;60(1):98-110. doi: 10.1373/clinchem.2013.205740. Epub 2013 Oct 29. Review.

11.

Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A.

Price JC, Pollock LM, Rudd ML, Fogoros SK, Mohamed H, Hanigan CL, Le Gallo M; NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Zhang S, Cruz P, Cherukuri PF, Hansen NF, McManus KJ, Godwin AK, Sgroi DC, Mullikin JC, Merino MJ, Hieter P, Bell DW.

PLoS One. 2013 Jun 3;8(6):e63313. doi: 10.1371/journal.pone.0063313. Print 2014.

12.

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.

Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, Sgroi DC; NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program, Hieter P, Mullikin JC, Merino MJ, Bell DW.

Nat Genet. 2012 Dec;44(12):1310-5. doi: 10.1038/ng.2455. Epub 2012 Oct 28.

13.

PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans.

Grall A, Guaguère E, Planchais S, Grond S, Bourrat E, Hausser I, Hitte C, Le Gallo M, Derbois C, Kim GJ, Lagoutte L, Degorce-Rubiales F, Radner FP, Thomas A, Küry S, Bensignor E, Fontaine J, Pin D, Zimmermann R, Zechner R, Lathrop M, Galibert F, André C, Fischer J.

Nat Genet. 2012 Jan 15;44(2):140-7. doi: 10.1038/ng.1056.

PMID:
22246504
14.

HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.

Fauquembergue E, Toutirais O, Tougeron D, Drouet A, Le Gallo M, Desille M, Cabillic F, de La Pintière CT, Iero M, Rivoltini L, Baert-Desurmont S, Leprince J, Vaudry H, Sesboué R, Frébourg T, Latouche JB, Catros V.

J Immunother. 2010 May;33(4):402-13. doi: 10.1097/CJI.0b013e3181d366da.

PMID:
20386466
15.

DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.

Toutirais O, Cabillic F, Le Friec G, Salot S, Loyer P, Le Gallo M, Desille M, de La Pintière CT, Daniel P, Bouet F, Catros V.

Eur J Immunol. 2009 May;39(5):1361-8. doi: 10.1002/eji.200838409.

16.

Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5.

Le Gallo M, Toutirais O, Montier T, Cabillic F, Bouet F, Delépine P, Lehn P, Jotereau F, Catros V.

J Gene Med. 2008 Jun;10(6):628-36. doi: 10.1002/jgm.1188.

PMID:
18338820
17.

Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.

Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pintière C, Daniel P, Genetet N, Meunier B, Dupont-Bierre E, Boudjema K, Catros V.

Cancer Immunol Immunother. 2008 Apr;57(4):531-9. Epub 2007 Sep 1.

PMID:
17764010

Supplemental Content

Loading ...
Support Center